Executive and social functioning in pediatric posterior fossa tumor survivors and healthy controls.
brain tumor
cerebellum
childhood cancer
executive functioning
social functioning
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Executive and social functioning difficulty is well established in pediatric brain tumor survivors. Few studies have compared posterior fossa (PF) tumor survivors in comparison to their peers. The relationship between attention, processing speed, working memory, fatigue, and executive and social functioning was investigated to better understand the factors that impact executive and social functioning in PF tumor populations. Sixteen medulloblastomas, 9 low-grade astrocytomas (LGAs), and 17 healthy controls recruited from 4 sites completed measures of working memory and processing speed, and self-reported fatigue. One parent completed questionnaires on executive and social functioning. There were no significant differences among all 3 groups on parent-reported executive and social functioning; of note, parents of LGA survivors expressed greater concerns regarding behavioral and cognitive regulation than did parents of medulloblastoma survivors and healthy controls. Parent-reported attention was related to parent-reported emotion, behavior, and cognitive regulation. Worse self-reported fatigue was associated with greater emotional dysregulation for the 2 PF tumor groups. Parents of PF tumor survivors described their children as performing similarly to their peers in most facets of executive and social functioning. While LGA survivors are traditionally thought to have more favorable outcomes, our finding of parent-reported executive functioning concerns to be worse for this group highlights the importance of long-term follow-up for all PF tumor survivors. Additionally, significant effects of attention on aspects of executive functioning in PF tumor survivors may inform current clinical practice and the future development of more effective interventions.
Sections du résumé
Background
UNASSIGNED
Executive and social functioning difficulty is well established in pediatric brain tumor survivors. Few studies have compared posterior fossa (PF) tumor survivors in comparison to their peers. The relationship between attention, processing speed, working memory, fatigue, and executive and social functioning was investigated to better understand the factors that impact executive and social functioning in PF tumor populations.
Methods
UNASSIGNED
Sixteen medulloblastomas, 9 low-grade astrocytomas (LGAs), and 17 healthy controls recruited from 4 sites completed measures of working memory and processing speed, and self-reported fatigue. One parent completed questionnaires on executive and social functioning.
Results
UNASSIGNED
There were no significant differences among all 3 groups on parent-reported executive and social functioning; of note, parents of LGA survivors expressed greater concerns regarding behavioral and cognitive regulation than did parents of medulloblastoma survivors and healthy controls. Parent-reported attention was related to parent-reported emotion, behavior, and cognitive regulation. Worse self-reported fatigue was associated with greater emotional dysregulation for the 2 PF tumor groups.
Conclusions
UNASSIGNED
Parents of PF tumor survivors described their children as performing similarly to their peers in most facets of executive and social functioning. While LGA survivors are traditionally thought to have more favorable outcomes, our finding of parent-reported executive functioning concerns to be worse for this group highlights the importance of long-term follow-up for all PF tumor survivors. Additionally, significant effects of attention on aspects of executive functioning in PF tumor survivors may inform current clinical practice and the future development of more effective interventions.
Identifiants
pubmed: 36970175
doi: 10.1093/nop/npac090
pii: npac090
pmc: PMC10037940
doi:
Types de publication
Journal Article
Langues
eng
Pagination
152-161Informations de copyright
Published by Oxford University Press 2022.
Déclaration de conflit d'intérêts
The authors have no conflict of interest to declare.
Références
Appl Neuropsychol Child. 2017 Oct-Dec;6(4):255-261
pubmed: 27182681
Child Neuropsychol. 2013;19(4):370-84
pubmed: 22420326
Neuropsychol Rehabil. 2021 Jan;31(1):129-153
pubmed: 31603026
J Clin Oncol. 2005 Aug 1;23(22):5198-204
pubmed: 16051961
J Clin Oncol. 2018 Sep 20;36(27):2762-2769
pubmed: 30091946
Cancer. 2006 Jan 15;106(2):396-402
pubmed: 16353203
Neuropsychology. 2020 Mar;34(3):350-358
pubmed: 31999166
Appl Neuropsychol Child. 2020 Jan-Mar;9(1):83-91
pubmed: 30501139
Neurooncol Pract. 2017 Jun;4(2):82-97
pubmed: 31385962
Cancer. 2004 Nov 1;101(9):2116-25
pubmed: 15389475
Pediatr Blood Cancer. 2014 Jul;61(7):1300-4
pubmed: 24616367
Brain. 2000 May;123 ( Pt 5):1051-61
pubmed: 10775549
Pediatr Blood Cancer. 2022 Feb;69(2):e29491
pubmed: 34842359
Front Hum Neurosci. 2013 Nov 07;7:746
pubmed: 24223546
J Int Neuropsychol Soc. 2010 May;16(3):495-505
pubmed: 20188014
Psychol Bull. 2007 May;133(3):535-56
pubmed: 17469991
J Pediatr Oncol Nurs. 2014 Mar-Apr;31(2):65-77
pubmed: 24608699
Psychol Bull. 2010 Jan;136(1):39-64
pubmed: 20063925
Psychooncology. 2018 Jan;27(1):91-98
pubmed: 28124799
J Child Psychol Psychiatry. 2013 Feb;54(2):131-43
pubmed: 23057693
Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):726-735
pubmed: 33243479
Childs Nerv Syst. 2015 Oct;31(10):1877-90
pubmed: 26351237
Appl Neuropsychol Child. 2022 Sep 16;:1-10
pubmed: 36111630
Support Care Cancer. 2019 Nov;27(11):4237-4244
pubmed: 30847703
Support Care Cancer. 2010 Dec;18(12):1499-513
pubmed: 20680353
J Natl Cancer Inst. 2014 Jul 30;106(8):
pubmed: 25080574
Cancer. 2002 Apr 1;94(7):2090-106
pubmed: 11932914
J Clin Oncol. 2010 Oct 10;28(29):4465-72
pubmed: 20837955
Pediatr Blood Cancer. 2015 Mar;62(3):375-84
pubmed: 25382825
Pediatr Hematol Oncol. 2018 Feb;35(1):76-89
pubmed: 29652554
J Pediatr Hematol Oncol. 2019 May;41(4):313-318
pubmed: 30475298
J Clin Oncol. 2005 Aug 20;23(24):5493-500
pubmed: 16110009
Clin Neurol Neurosurg. 2008 Sep;110(8):763-73
pubmed: 18602745
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376154
Cerebellum. 2020 Feb;19(1):102-125
pubmed: 31522332
Childs Nerv Syst. 2015 Oct;31(10):1869-75
pubmed: 26351236
Cancer. 2011 Jun 1;117(11):2559-68
pubmed: 21484777
Qual Life Res. 2016 Feb;25(2):435-446
pubmed: 26289022
J Pediatr Psychol. 2021 Jan 20;46(1):80-90
pubmed: 33377489
Childs Nerv Syst. 2020 Jun;36(6):1205-1214
pubmed: 31240391